1 Anderson JL, Knowlton KU, May HT, Bair TL, Armstrong SO, Lappe DL, Muhlestein JB (2018) Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study. J Clin Lipidol 12 (4): 1008-1018.e1001 DOI 10.1016/j.jacl.2018.03.084
2 Hirsh BJ, Smilowitz NR, Rosenson RS, Fuster V, Sperling LS (2015) Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome: Opportunities for Improvement. J Am Coll Cardiol 66 (2): 184-192
3 Tungsubutra W, Phongtuntakul B (2015) Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction. J Med Assoc Thai 98 (2): 129-136
4 Zhao SP (2016) Amendment of the low-density lipoprotein cholesterol target in the ‘Chinese Guidelines for the Prevention and Treatment of Adult Dyslipidemia’: Opinion. Chron Dis & Transl Med 2 (1): 7-9
5 Heintjes EM, Penning-van Beest FJ, Plat AW, Meerding WJ, Webb K, Sturkenboom MC, Herings RM (2012) Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice. Pharmacotherapy 32 (7): 631-641 DOI 10.1002/j.1875-9114.2011.01086.x
6 Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Jr., Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC, Jr., Tomaselli GF (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 (25 Suppl 2): S1-45 DOI 10.1161/01.cir.0000437738.63853.7a
7 Mahmood D, Jahan K, Habibullah K (2015) Primary prevention with statins in cardiovascular diseases: A Saudi Arabian perspective. J Saudi Heart Assoc 27 (3): 179-191 DOI 10.1016/j.jsha.2014.09.004
8 Zhu JR, Gao RL, Zhao SP, Guoping LU, Zhao D, Jianjun LI, Zhu JR, Gao RL, Zhao SP, Guoping LU (2018) 2016 Chinese guidelines for the management of dyslipidemia in adults. Journal of Geriatric Cardiology Jgc 15 (1): 1-29
9 Salami JA, Warraich H, Valero-Elizondo J, Spatz ES, Desai NR, Rana JS, Virani SS, Blankstein R, Khera A, Blaha MJ, Blumenthal RS, Lloyd-Jones D, Nasir K (2017) National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey. JAMA Cardiol 2 (1): 56-65 DOI 10.1001/jamacardio.2016.4700
10 O'Keeffe AG, Nazareth I, Petersen I (2016) Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health Improvement Network primary care data. Clin Epidemiol 8: 123-132 DOI 10.2147/clep.s104258
11 Valentino M, Al Danaf J, Panakos A, Ragupathi L, Duffy D, Whellan D (2016) Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke. Am Heart J 181: 130-136 DOI 10.1016/j.ahj.2016.07.024
12 Hsieh HC, Hsu JC, Lu CY (2017) 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. BMJ Open 7 (5): e014150 DOI 10.1136/bmjopen-2016-014150
13 Blais JE, Chan EW, Law SWY, Mok MT, Huang D, Wong ICK, Siu CW (2019) Trends in statin prescription prevalence, initiation, and dosing: Hong Kong, 2004-2015. Atherosclerosis 280: 174-182 DOI 10.1016/j.atherosclerosis.2018.11.015
14 Harrison TN, Scott RD, Cheetham TC, Chang SC, Hsu JY, Wei R, Ling Grant DS, Boklage SH, Romo-LeTourneau V, Reynolds K (2018) Trends in Statin Use 2009-2015 in a Large Integrated Health System: Pre- and Post-2013 ACC/AHA Guideline on Treatment of Blood Cholesterol. Cardiovasc Drugs Ther 32 (4): 397-404 DOI 10.1007/s10557-018-6810-1
15 Joint Committee for Developing Chinese guidelines on Prevention and Treatment of Dyslipidemia in Adults (2016) [Chinese guidelines on prevention and treatment of dyslipidemia in adults (2016 Revised version)]. Chin J Circ. 16: 15-35.
16 Li X, Xu Y, Li J, Hu D (2009) The gender differences in baseline characteristics and statin intervention among outpatients with coronary heart disease in China: the China Cholesterol Education Program. Clinical Cardiology: An International Indexed and Peer‐Reviewed Journal for Advances in the Treatment of Cardiovascular Disease 32 (6): 308-314
17 Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care: 1130-1139
18 Laleman N, Henrard S, van den Akker M, Goderis G, Buntinx F, Van Pottelbergh G, Vaes B (2018) Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study. BMC Cardiovasc Disord 18 (1): 209 DOI 10.1186/s12872-018-0941-y
19 Sun W, Zhou Y, Zhang Z, Cao L, Chen W (2017) The Trends in Cardiovascular Diseases and Respiratory Diseases Mortality in Urban and Rural China, 1990-2015. Int J Environ Res Public Health 14 (11) DOI 10.3390/ijerph14111391
20 Chen Weiwei, Gao Runlin, Liu Lisheng, Manlu Zhu, Wen Wang, Yongjun Wang (2018) China cardiovascular disease report 2017: a summary. Chin J Circ 1: 1-8.
21 Brown F, Singer A, Katz A, Konrad G (2017) Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. Can Fam Physician 63 (11): e495-e503
22 Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL (2015) Trends in Prescription Drug Use Among Adults in the United States From 1999-2012. J Am Med Assoc 314 (17): 1818
23 Tomé-Carneiro J, Gonzálvez M, Larrosa M, Yáñez-Gascón MJ, García-Almagro FJ, Ruiz-Ros JA, Tomás-Barberán FA, García-Conesa MT, Espín JC (2013) Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective. Ann N Y Acad Sci 1290 (1): 37-51
24 Huang BT, Peng Y, Huang FY, Xia TL, Gui YY, Liao YB, Pu XB, Chen SJ, Yang Y, Chen M (2017) Trends in prescribing rate of statins at discharge and modifiable factors in patients with atherosclerotic cardiovascular disease. Intern Emerg Med 12 (8): 1121-1129 DOI 10.1007/s11739-017-1694-9
25 Hartz I, Sakshaug S, Furu K, Engeland A, Eggen AE, Njolstad I, Skurtveit S (2007) Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study. BMC Clin Pharmacol 7: 14 DOI 10.1186/1472-6904-7-14
26 Moon JC, Bogle RG (2006) Switching statins. BMJ 332 (7554): 1344-1345 DOI 10.1136/bmj.332.7554.1344
27 Martikainen JE, Saastamoinen LK, Korhonen MJ, Enlund H, Helin-Salmivaara A (2010) Impact of Restricted Reimbursement on the Use of Statins in Finland: A Register-Based Study. Med Care 48 (9): 761-766
28 Damiani G, Federico B, Anselmi A, Silvestrini G, Iodice L, Navarra P, Cas RD, Raschetti R, Ricciardi W (2014) The impact of Regional co-payment and National reimbursement criteria on statins use in Italy: an interrupted time-series analysis. BMC Health Services Research,14,1(2014-01-06) 14 (1): 6-6
29 Sakshaug S, Furu K, O, Ronning M, Skurtveit S (2010) Switching statins in Norway after new reimbursement policy: a nationwide prescription study. Br J Clin Pharmacol 64 (4): 476-481
30 Gitt AK, Juenger C, Smolka W, Wood D, Kastelein J (2013) Impact of a budget-restrictive (Germany) versus an incentive-driven (UK) reimbursement system on LDL-goal-achievement in statin-treated patients for secondary prevention: results of DYSIS. Eur Heart J 34 (suppl 1): 3689-3689
31 Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P (2009) Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. Expert Rev Pharmacoecon Outcomes Res 9 (5): 475
32 Virani SS, Steinberg L, Murray T, Negi S, Nambi V, Woodard LD, Bozkurt B, Petersen LA, Ballantyne CM (2011) Barriers to non-HDL cholesterol goal attainment by providers. Am J Med 124 (9): 876-880 e872 DOI 10.1016/j.amjmed.2011.02.012
33 Vijayakrishnan R, Kalyatanda G, Srinivasan I, Abraham GM (2013) Compliance with the Adult Treatment Panel III guidelines for hyperlipidemia in a resident-run ambulatory clinic: a retrospective data analysis. J Clin Lipidol 7 (1): 43-47 DOI 10.1016/j.jacl.2012.06.004
34 Rosenson RS, Kent ST, Brown TM, Farkouh ME, Levitan EB, Yun H, Sharma P, Safford MM, Kilgore M, Muntner P (2015) Underutilization of High-Intensity Statin Therapy After Hospitalization for CoronaryHeart Disease. J Am Coll Cardiol 65 (3): 270-277
35 Jamé S, Wittenberg E, Potter MB, Fleischmann KE (2015) The new lipid guidelines: what do primary care clinicians think? Am J Med 128 (8): 914.e915-914.e910
36 Elisabeth AB, Denig P, Vliet TV, Dekker JH (2009) Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative study. BMC Fam Pract 10 (1): 24-24
37 Huang Q, Grabner M, Sanchez RJ, Willey VJ, Cziraky MJ, Palli SR, Power TP (2016) Clinical Characteristics and Unmet Need Among Patients with Atherosclerotic Cardiovascular Disease Stratified by Statin Use. Am Health Drug Benefits 9 (8): 434-444
38 Olufade T, Zhou S, Anzalone D, Kern DM, Tunceli O, Cziraky MJ, Willey VJ (2017) Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan. J Am Heart Assoc 6 (5) DOI 10.1161/jaha.116.005205
39 Zupec JF, Marrs JC, Saseen JJ (2016) Evaluation of Statin Prescribing for Secondary Prevention in Primary Care Following New Guideline Recommendations. Ann Pharmacother 50 (1): 17-21 DOI 10.1177/1060028015608199
40 Zhang H, Plutzky J, Shubina M, Turchin A (2016) Risk factors for lack of statin therapy in patients with diabetes and coronary artery disease. J Clin Lipidol 10 (6): 1406-1413 DOI 10.1016/j.jacl.2016.09.010
41 Li XN, Xu HR, Chen WL, Chu NN, Zhu JR (2010) Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: A randomized, open-label, ascending single- and multiple-dose study. Clin Ther 32 (3): 575-587